Noncatalytic Bruton's tyrosine kinase activates PLCγ2 variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells
Martin Wist, Laura Meier, Orit Gutman, Jennifer Haas, Sascha Endres, Yuan Zhou, R. Rosler, Sebastian Wiese, Stephan Stilgenbauer, Elias Hobeika, Yoav I. Henis, Peter Gierschik, Claudia Walliser
Abstract
Because catalytically-inactive BTK is insensitive to active-site BTK inhibitors, the mechanism involving the noncatalytic BTK uncovered here may contribute to preexisting reduced sensitivity or even primary resistance of CLL to these drugs.
Topics & Concepts
IbrutinibBruton's tyrosine kinaseChronic lymphocytic leukemiaTyrosine kinaseCancer researchLeukemiaLymphocytic infiltrationImmunologyMedicineBiologyReceptorInternal medicineChronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentGlycosylation and Glycoproteins Research